Ergomed Share Chat (ERGO)

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
Ergomed	LSE:ERGO	London	Ordinary Share	GB00BN7ZCY67	ORD 1P

	Price Change	% Change	Share Price	Bid Price	Offer Price	High Price	Low Price	Open Price	Shares Traded	Last Trade
	+3.00p	+1.66%	184.00p	182.00p	186.00p	184.50p	180.00p	180.00p	20,000	12:39:01

Industry Sector	Turnover (m)	Profit (m)	EPS - Basic	PE Ratio	Market Cap (m)
Pharmaceuticals & Biotechnology	54.1	-10.8	-20.0	-	84.94

Ergomed Share Discussion Threads

Showing 276 to 297 of 300 messages

Chat Pages: 12 11 10 9 8 7 6 5 4 3 2 1

Date	Subject	Author	Discuss
10/4/2019 01:38	Wonder if they will have to write off Haemostatix? No Phase 3 deal a year after supposedly great Phase 2 results - doesn’t sound good to me. Why don’t they do it themselves? Maybe they will if Multikine turns out to be a winner. It looks like Multikine is the last chance on the partnered drugs. The only other one was the Ferrer drug and like Haemostatix the Phase 2 results were touted as great but clearly they weren’t as no partners have been found to take the drug forward into Phase 3. CROs may be good at conducting trials but they seem to be poor at knowing whether the drugs will be winners.	jamtomorrow2	Read Full Thread Reply
09/4/2019 15:33	Buys coming in. Let's see what tomorrow brings...	mfhmfh	Read Full Thread Reply
06/4/2019 23:08	Interesting that Cel-Sci’s share price has doubled recently on optimism that Multikine’s trial will be successful. Ergomed has an interest in this drug.	jamtomorrow2	Read Full Thread Reply
31/1/2019 14:41	Slater Investments Ltd above 10%	mfhmfh	Read Full Thread Reply
21/1/2019 08:29	Oryx International Growth Fund above 8%	mfhmfh	Read Full Thread Reply
22/11/2018 14:17	big volume today	mfhmfh	Read Full Thread Reply
06/11/2018 15:37	Octopus bailing?	jamtomorrow2	Read Full Thread Reply
31/10/2018 16:42	Agreed - thanks for the link	sicilian_kan	Read Full Thread Reply
31/10/2018 16:02	They have certainly pushed up thier eps for this and next year. Looks rather interesting,	sidam	Read Full Thread Reply
31/10/2018 15:07	Latest note from ED. https://www.equitydevelopment.co.uk/edreader/?ltkn=c39c859d40f5867e7315886ef7d8986aZlaE3Wj6&d=%3D%3DAO5QjM	edmonda	Read Full Thread Reply
18/9/2018 10:13	Interim Results tomorrow	piedro	Read Full Thread Reply
16/8/2018 09:12	AIM:ERGO - "building for growth" At the Full Year results, the new CEO Stephen Stamp outlined a value-enhancing vision for the business: a move away from co-development projects towards its existing Clinical Research Services (CRS) and its drug safety and medical information (DS&MI) businesses. Both the CRS and DS&MI businesses have been providing clear, repeatable project revenues and these markets are growing substantially. However, a number of issues have impacted business performance in the first six months of the year including the delay in the timing of a few key contracts and the lag effect of training up new staff to cope with the influx of expected work over the next few years. The former impacted revenues, the latter weighed on costs. Our FY2018 and FY2019 estimates have been trimmed to reflect the revised projections. Updating our valuation using peer-based metrics of c1.8x EV/Sales and c18x PE gives a fair value for the Services businesses (CRS and DS&MI) of 215p / share. The Development and Haemostatix businesses add a further 120p to that, based on an NPV (Net Present Value) analysis. Read the full note here ... https://www.equitydevelopment.co.uk/edreader/?d=%3D%3DQO1QjM	edmonda	Read Full Thread Reply
01/7/2018 14:58	There is a recent report on Ergomed’s AGM which is available to read in our full member exclusive area here: hTTps://www.sharesoc.org/members-area/	sharesoc	Read Full Thread Reply
29/6/2018 13:14	Ergomed to present to investors at the upcoming Proactive One2One Forum on 12th July in London. For details and registration, click here: https://tinyurl.com/ybq4tya2	aim_trader	Read Full Thread Reply
28/6/2018 13:40	In a note to clients, analysts at Numis said that as Ergomed “is constantly hiring ahead of anticipated revenue growth”, a delay in anticipated revenue was going to drive margins lower as utilisation dropped. They added: “We downgrade our revenues by c.5% to £46.5mln primarily hitting the CRO division (£19.0mln from £21.6mln), with top line growth in PV [PrimeVigilance division] slightly higher, but on a higher cost base (reduced gross margins in both divisions) which effectively delays our EBITDA ramp by one year.” The broker was, however, fairly ambivalent regarding the delay: “Contract delays are a frequent occurrence in the CRO business, while in the PV division trading seems to have been in line with or slightly ahead of our expectations, while management planned for more.” hTTp://www.p roactiveinvestors.co.uk/companies/news/199777/ergomed-revenue-delay-leads-to-numis-downgrade-199777.html	sicilian_kan	Read Full Thread Reply
28/6/2018 10:50	It is the companies second profits warning in the last year. Shares are now back to where they were a couple of months ago. I don't think you can complain you have been overly hard done by. The multiple is hardly cheap,	horndean eagle	Read Full Thread Reply
28/6/2018 09:17	Yes, think disastrous RNS is probably a bit OTT - very disappointing more like it, especially given the Company's previous bullish statements.	bermudashorts	Read Full Thread Reply
28/6/2018 09:12	what current market cap? Seems toppy..	tsmith2	Read Full Thread Reply
28/6/2018 09:02	Mirabeau this isn't really a pharma stock. It is a CRO with a pharmacovigilance arm that it is expanding.	sicilian_kan	Read Full Thread Reply
28/6/2018 08:46	What a mess. I only set up the thread and never held a position but how many pharma stocks in recent weeks have released seriously disastrous RNSs...too numerous to mention	mirabeau	Read Full Thread Reply
28/6/2018 08:44	Seems completely overdone to me. - 5% reduction in revenue compared to market consensus, yet a 33% reduction in share price. - 2018 EBITDA still going to be ahead of 2017's £2.8m - Backlog of contracts still strong and increase on last years - The Company's cash position remains strong with positive cash flows in the period. I have only a small amount here. Invested 18 months ago on a 5 year basis. See no reason to bail out. Strategy and management still seem strong and am excited by the pharmacovigilance opportunities.	sicilian_kan	Read Full Thread Reply
25/5/2018 16:44	Agreed and a nice rise too. I think we should be looking at testing 300p at some point in the coming weeks / months.	sicilian_kan	Read Full Thread Reply

Chat Pages: 12 11 10 9 8 7 6 5 4 3 2 1

Your Recent History

LSE

ERGO

Ergomed

Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.